Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 18/20 | 1.00 |
| ▸ | GAA | P10253 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033202 | 1.00 | MAPT (1.00) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL17717644 | 0.74 | F2 (0.65) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL10476361 | 0.74 | MAPT (0.75) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL880461 | 0.72 | MAPT (0.76) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL23498169 | 0.72 | MAPT (0.70) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL9458235 | 0.70 | MAPT (0.70) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL28215466 | 0.70 | MAPT (0.67) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL19459381 | 0.70 | MAPT (0.70) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL8343557 | 0.70 | MAPT (0.69) | MAPTGAAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL8343548 | 0.70 | MAPT (0.69) | MAPTGAAKDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | claimed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | MAPT 4421/4885GAA 1015/4885KDM4E 3193/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | MAPT 4601/4885GAA 764/4885KDM4E 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.